Search research articles
Contact Us
Filters
Showing results (141-150 of 200) with videos related to
Page
of 20
Sort By:
International Journal of Cancer
|
August 9, 2006
Molecular determinants of irinotecan efficacy
Daniel Vallböhmer, Syma Iqbal, Dong Yun Yang, et al.
BMJ Open Respiratory Research
|
June 27, 2023
Comparison of mathematically arterialised venous blood gas sampling with arterial, capillary, and venous sampling in adult patients with hypercapnic respiratory failure: a single-centre longitudinal cohort study
Michael Gordon Davies, Dariusz Rafal Wozniak, Timothy George Quinnell, et al.
Drug Metabolism Letters
|
April 10, 2009
ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan
Katrin E Rhodes, Wu Zhang, Dongyun Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 27, 2004
A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy
Alan Sandler, Michael Gordon, Dinesh P De Alwis, et al.
Annual Review of Phytopathology
|
September 9, 2024
Biotechnology and Genomic Approaches to Mitigating Disease Impacts on Forest Health
Jared M LeBoldus, Shannon C Lynch, Andrew E Newhouse, et al.
American Journal of Medical Genetics. Part A
|
April 9, 2025
Non-Mosaic Trisomy 9: Further Delineation of the Clinical Phenotype
Courtney P Verscaj, Michael Gordon, Bradley D Holbrook, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 24, 2009
Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors
William P Tew, Michael Gordon, John Murren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 18, 2008
Clinical determinants of response to irinotecan-based therapy derived from cell line models
Wendy L Allen, Vicky M Coyle, Puthen V Jithesh, et al.
Pharmacogenetics and Genomics
|
June 22, 2006
Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab
Wu Zhang, Michael Gordon, Oliver A Press, et al.
Journal of Substance Abuse Treatment
|
February 26, 2017
Do patient characteristics moderate the effect of extended-release naltrexone (XR-NTX) for opioid use disorder?
Peter D Friedmann, Donna Wilson, Edward V Nunes, et al.
Page
of 20
Search research articles
Search
Showing results (141-150 of 200) with videos related to
Sort By:
Page
of 20
International Journal of Cancer
|
August 9, 2006
Molecular determinants of irinotecan efficacy
Daniel Vallböhmer, Syma Iqbal, Dong Yun Yang, et al.
BMJ Open Respiratory Research
|
June 27, 2023
Comparison of mathematically arterialised venous blood gas sampling with arterial, capillary, and venous sampling in adult patients with hypercapnic respiratory failure: a single-centre longitudinal cohort study
Michael Gordon Davies, Dariusz Rafal Wozniak, Timothy George Quinnell, et al.
Drug Metabolism Letters
|
April 10, 2009
ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan
Katrin E Rhodes, Wu Zhang, Dongyun Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 27, 2004
A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy
Alan Sandler, Michael Gordon, Dinesh P De Alwis, et al.
Annual Review of Phytopathology
|
September 9, 2024
Biotechnology and Genomic Approaches to Mitigating Disease Impacts on Forest Health
Jared M LeBoldus, Shannon C Lynch, Andrew E Newhouse, et al.
American Journal of Medical Genetics. Part A
|
April 9, 2025
Non-Mosaic Trisomy 9: Further Delineation of the Clinical Phenotype
Courtney P Verscaj, Michael Gordon, Bradley D Holbrook, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 24, 2009
Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors
William P Tew, Michael Gordon, John Murren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 18, 2008
Clinical determinants of response to irinotecan-based therapy derived from cell line models
Wendy L Allen, Vicky M Coyle, Puthen V Jithesh, et al.
Pharmacogenetics and Genomics
|
June 22, 2006
Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab
Wu Zhang, Michael Gordon, Oliver A Press, et al.
Journal of Substance Abuse Treatment
|
February 26, 2017
Do patient characteristics moderate the effect of extended-release naltrexone (XR-NTX) for opioid use disorder?
Peter D Friedmann, Donna Wilson, Edward V Nunes, et al.
Page
of 20